Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Peptide

PEG-MGF

Also known as PEGylated mechano growth factor

In vitro — evidence level 1 of 4: In-vitro evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A PEGylated form of MGF with no primary published study of its own at any evidence level.

Category
Peptide
Highest evidence level identified
In-vitro evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

PEG-MGF is described as MGF with polyethylene glycol attached, a modification intended to slow enzymatic degradation and extend circulating half-life. The proposed mechanism is otherwise identical to MGF. No published primary study was located that tests this proposition for the PEGylated form specifically, so the mechanism is inferred from the parent compound rather than demonstrated for this one.

Research areas

  • Muscle biology
  • Growth factor signalling

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

None specific to this compound. Repeated searches across its several names returned no primary study — only a narrative review that lists it, a methods paper using the parent compound as a model analyte, and delivery-system papers concerning the non-PEGylated form.

Animal evidence

Studies in living non-human animals.

None located.

Human observational evidence

Studies observing people without assigning an intervention.

None located.

Clinical-trial evidence

Studies assigning an intervention to human participants.

None. No registered trial was found.

Study limitations

  • The evidence level shown is the lowest the framework offers, and it overstates the position. No primary published study of this compound exists at any level, including in vitro. It is recorded at the floor of the scale rather than as a finding that laboratory data exists.
  • All mechanistic claims are extrapolated from MGF, whose own key finding failed independent replication.
  • The widely circulated half-life figures for this compound trace only to vendor marketing pages. No peer-reviewed pharmacokinetic characterisation was found.
  • The degree and site of PEGylation are unstandardised, so products sold under this name are not necessarily the same molecule as one another.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

There are no safety data for this compound from any controlled study. A 2026 review groups it with unregulated IGF-1 analogues and reports that adverse effects across that class span endocrine and metabolic disturbance, fluid retention, musculoskeletal symptoms and injection-site reactions, while noting uncertainty over product composition in unregulated supply. Nothing specific to this compound can be stated from evidence.

References